North America preventive vaccines market is projected to grow by 6.3% annually in the forecast period and reach $46.90 billion by 2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for preventive vaccines such as COVID-19 vaccines, and the increasing healthcare expenditure.
Highlighted with 52 tables and 51 figures, this 132-page report “North America Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify North America preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Country.
Based on Vaccine Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Live/Attenuated Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• Toxoid Vaccines
• Conjugate Vaccines
• mRNA Vaccines
• Recombinant Vector Vaccines
• Other Vaccines
Based on Disease, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Pneumococcal Disease
• Poliovirus
• Hepatitis
• Influenza
• Measles, Mumps, and Rubella (MMR)
• Varicella
• Human Papilloma Virus
• COVID-19
• Other Diseases
By Administration, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Intramuscular Route
• Subcutaneous Route
• Oral Route
• Intravenous Injection
• Other Administration Routes
By Patient, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Pediatric Vaccines
o Pneumococcal
o Measles, Mumps, and Rubella (MMR)
o Varicella
o Hepatitis
o Poliovirus
o Haemophilus Influenzae B (HIB)
o Other Diseases
• Adult Vaccines
o Influenza
o Cervical Cancer
o Hepatitis
o Zoster
o Other Diseases
Geographically, the following national/local markets are fully investigated:
• U.S.
• Canada
• Mexico
For each key country, detailed analysis and annual revenue ($ mn) are available for 2022-2032. The breakdown of national markets by Vaccine Type, Disease, and Administration over the forecast years are also included.
The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co.
Moderna Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
1 Introduction 8
1.1 Industry Definition and Research Scope 8
1.1.1 Industry Definition 8
1.1.2 Research Scope 9
1.2 Research Methodology 12
1.2.1 Overview of Market Research Methodology 12
1.2.2 Market Assumption 13
1.2.3 Secondary Data 13
1.2.4 Primary Data 13
1.2.5 Data Filtration and Model Design 14
1.2.6 Market Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 Market Overview and Dynamics 20
2.1 Market Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the Market 25
2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery 27
2.2 Major Growth Drivers 31
2.3 Market Restraints and Challenges 37
2.4 Emerging Opportunities and Market Trends 40
2.5 Porter’s Fiver Forces Analysis 44
3 Segmentation of North America Market by Vaccine Type 48
3.1 Market Overview by Vaccine Type 48
3.2 Live/Attenuated Vaccines 50
3.3 Inactivated Vaccines 51
3.4 Subunit Vaccines 52
3.5 Toxoid Vaccines 53
3.6 Conjugate Vaccines 54
3.7 mRNA Vaccines 55
3.8 Recombinant Vector Vaccines 56
3.9 Other Vaccines 57
4 Segmentation of North America Market by Disease 58
4.1 Market Overview by Disease 58
4.2 Pneumococcal Disease 60
4.3 Poliovirus 61
4.4 Hepatitis 62
4.5 Influenza 63
4.6 Measles, Mumps, and Rubella (MMR) 64
4.7 Varicella 65
4.8 Human Papilloma Virus 66
4.9 COVID-19 67
4.10 Other Diseases 68
5 Segmentation of North America Market by Administration 69
5.1 Market Overview by Administration 69
5.2 Intramuscular Route 71
5.3 Subcutaneous Route 72
5.4 Oral Route 73
5.5 Intravenous Injection 74
5.6 Other Administration Routes 75
6 Segmentation of North America Market by Patient 76
6.1 Market Overview by Patient 76
6.2 Pediatric Vaccines 78
6.3 Adult Vaccines 80
7 North America Market 2022-2032 by Country 82
7.1 Overview of North America Market 82
7.2 U.S. 85
7.3 Canada 89
7.4 Mexico 92
8 Competitive Landscape 95
8.1 Overview of Key Vendors 95
8.2 New Product Launch, Partnership, Investment, and M&A 98
8.3 Company Profiles 99
AstraZeneca plc 99
Bavarian Nordic A/S 101
China National Biotec Group Company Ltd. 104
CSL Ltd. 106
Daiichi Sankyo Co. Ltd 108
Emergent BioSolutions Inc. 110
GlaxoSmithKline plc 112
Johnson & Johnson 116
Merck & Co. 118
Moderna Inc. 120
Novavax, Inc. 121
Pfizer Inc. 123
Sanofi SA 127
Takeda Pharmaceutical Co. Ltd. 130
RELATED REPORTS 132
List of Tables:
Table 1. Snapshot of North America Preventive Vaccines Market in Balanced Perspective, 2022-2032 18
Table 2. World Economic Outlook, 2021-2031 23
Table 3. World Economic Outlook, 2021-2023 24
Table 4. Scenarios for Economic Impact of Ukraine Crisis 28
Table 5. World Health Spending by Region, $ bn, 2013-2020 36
Table 6. Main Product Trends and Market Opportunities in North America Preventive Vaccines Market 40
Table 7. North America Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 48
Table 8. North America Preventive Vaccines Market by Disease, 2022-2032, $ mn 58
Table 9. North America Preventive Vaccines Market by Administration, 2022-2032, $ mn 69
Table 10. North America Preventive Vaccines Market by Patient, 2022-2032, $ mn 76
Table 11. North America Preventive Vaccines Market: Pediatric Vaccines by Disease, 2022-2032, $ mn 79
Table 12. North America Preventive Vaccines Market: Adult Vaccines by Disease, 2022-2032, $ mn 81
Table 13. North America Preventive Vaccines Market by Country, 2022-2032, $ mn 83
Table 14. U.S. Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 87
Table 15. U.S. Preventive Vaccines Market by Disease, 2022-2032, $ mn 87
Table 16. U.S. Preventive Vaccines Market by Administration, 2022-2032, $ mn 88
Table 17. Canada Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 90
Table 18. Canada Preventive Vaccines Market by Disease, 2022-2032, $ mn 90
Table 19. Canada Preventive Vaccines Market by Administration, 2022-2032, $ mn 91
Table 20. Mexico Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 93
Table 21. Mexico Preventive Vaccines Market by Disease, 2022-2032, $ mn 93
Table 22. Mexico Preventive Vaccines Market by Administration, 2022-2032, $ mn 94
Table 23. AstraZeneca plc: Company Snapshot 99
Table 24. AstraZeneca plc: Business Segmentation 100
Table 25. AstraZeneca plc: Product Portfolio 100
Table 26. Bavarian Nordic A/S: Company Snapshot 101
Table 27. Bavarian Nordic A/S: Marketed Products and Pipeline, as of July 2020 102
Table 28. China National Biotec Group Company Ltd.: Company Snapshot 104
Table 29. CSL Ltd.: Company Snapshot 106
Table 30. Daiichi Sankyo Co. Ltd.: Company Snapshot 108
Table 31. Emergent BioSolutions Inc.: Company Snapshot 110
Table 32. GlaxoSmithKline: Company Snapshot 112
Table 33. GlaxoSmithKline: Business Segmentation 113
Table 34. GlaxoSmithKline: Product Portfolio 114
Table 35. GlaxoSmithKline: Revenue, 2018-2020, $ bn 115
Table 36. GlaxoSmithKline: Recent Developments 115
Table 37. Johnson & Johnson: Company Snapshot 116
Table 38. Johnson & Johnson: Business Segments 117
Table 39. Merck & Co., Inc.: Company Snapshot 118
Table 40. Merck & Co., Inc.: Business Segmentation 118
Table 41. Merck & Co., Inc.: Revenue, 2018-2020, $ bn 119
Table 42. Moderna Inc.: Company Snapshot 120
Table 43. Novavax, Inc.: Company Snapshot 121
Table 44. Pfizer Inc.: Company Snapshot 123
Table 45. Pfizer Inc.: Business Segmentation 124
Table 46. Pfizer Inc.: Product Portfolio 125
Table 47. Pfizer Inc.: Revenue, 2018-2020, $ bn 126
Table 48. Pfizer Inc.: Recent Developments 126
Table 49. Sanofi: Company Snapshot 127
Table 50. Sanofi: Business Segmentation 127
Table 51. Sanofi: Revenue, 2018-2020, $ bn 129
Table 52. Takeda Pharmaceutical Co. Ltd.: Company Snapshot 130
